

Arun Swaminath

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8854003/arun-swaminath-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69

papers

1,366

citations

19

h-index

36

g-index

86

ext. papers

1,730

ext. citations

5.1

avg, IF

4.37

L-index

#	Paper	IF	Citations
69	CXCR1+ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22. <i>Journal of Experimental Medicine</i> , 2014 , 211, 1571-83	16.6	262
68	The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1147-55	0.7	198
67	Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 2026-33	4.5	100
66	Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1345	0.7	87
65	Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 645-656	6.1	77
64	Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn's colitis. <i>Inflammatory Bowel Diseases</i> , 2008 , 14, 213-6	4.5	72
63	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018 , 155, 687-695.e10	13.3	60
62	Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1533-1540.e2	6.9	40
61	Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 2461-2467	4.5	33
60	Infliximab-induced autoimmune hepatitis with successful switch to adalimumab in a patient with Crohn's disease: the index case. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 3386-8	4	31
59	Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease. <i>Journal of Clinical Neuromuscular Disease</i> , 2012 , 13, 137-45	1.1	25
58	Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2497-2505.e1	6.9	25
57	Fatigue in Inflammatory Bowel Diseases: Etiologies and Management. <i>Advances in Therapy</i> , 2020 , 37, 97-112	4.1	24
56	The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 427-435	4.5	24
55	Video capsule endoscopy in inflammatory bowel disease: past, present, and future redux. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1254-62	4.5	22
54	Use of methotrexate in inflammatory bowel disease in 2014: A User's Guide. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2014 , 5, 113-21	3	22
53	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2952-2961.e8	6.9	21

52	Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 669-681	6.1	21
51	A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease. <i>Gastroenterology</i> , 2021 , 161, 837-852.e9	13.3	19
50	Donning a New Approach to the Practice of Gastroenterology: Perspectives From the COVID-19 Pandemic Epicenter. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1673-1681	6.9	18
49	Practice patterns in the use of anti-tumor necrosis factor alpha agents in the management of Crohn's disease: a US national practice survey comparing experts and non-experts. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 1160-4	4	15
48	Review of inflammatory bowel disease and COVID-19. <i>World Journal of Gastroenterology</i> , 2020 , 26, 5534-5542	5.5	13
47	TNF-alpha antagonist induced lupus on three different agents. <i>Postgraduate Medicine</i> , 2017 , 129, 304-307	3.7	10
46	Refractory urticarial vasculitis as a complication of ulcerative colitis successfully treated with rituximab. <i>Journal of Clinical Rheumatology</i> , 2011 , 17, 281-3	1.1	10
45	Optimizing drug therapy in inflammatory bowel disease. <i>Current Gastroenterology Reports</i> , 2007 , 9, 513-20	3.0	10
44	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	10
43	Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 775-781	4.5	10
42	Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 1854-1861	4.5	9
41	Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 2444-9	4.5	9
40	488 Early Institution of Tinidazole May Prevent Pouchitis Following Ileal-Pouch Anal Anastomosis (IPAA) Surgery in Ulcerative Colitis (UC) Patients. <i>Gastroenterology</i> , 2010 , 138, S-69	13.3	9
39	When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 1139-46	5.6	9
38	The power of poop: patients getting ahead of their doctors using self-administered fecal transplants. <i>American Journal of Gastroenterology</i> , 2014 , 109, 777-8	0.7	8
37	DOP009 Comparative safety profile of vedolizumab and tumour necrosis factor antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, S036-S036	1.5	8
36	Internet Searches About Therapies Do Not Impact Willingness to Accept Prescribed Therapy in Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 1013-20	4	7
35	The Course of SARS-COV2 Infection Was Not Severe in a Crohn's Patient Who Administered Maintenance Anti-TNF Therapy Overlapping the Early Pre-Symptomatic Period of Infection. <i>Antibodies</i> , 2020 , 9,	7	7

34	A rare endoscopic finding: severely ulcerated giant sigmoid diverticulum. <i>Gastrointestinal Endoscopy</i> , 2018 , 87, 1159-1160	5.2	3
33	Effect of physician education and patient counseling on inpatient nonsurgical percutaneous feeding tube placement rate, indications, and outcome. <i>Southern Medical Journal</i> , 2010 , 103, 126-30	0.6	3
32	COVID-19 Vaccination and Inflammatory Bowel Disease: Desired Antibody Responses, Future Directions, and a Note of Caution. <i>Gastroenterology</i> , 2021 ,	13.3	3
31	Mortality Risk of Inflammatory Bowel Disease: A Case-Control Study of New York State Death Records. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 1604-1611	4	3
30	The Comb Sign in Crohn's Ileocolitis. <i>Journal of General Internal Medicine</i> , 2018 , 33, 773	4	2
29	Tu1908 Safety of Vedolizumab in Inflammatory Bowel Disease in a Multi-Center Real World Consortium. <i>Gastroenterology</i> , 2016 , 150, S974	13.3	2
28	Sa1888 Efficacy and Predictors of Outcomes of Vedolizumab for Ulcerative Colitis in Clinical Practice. <i>Gastroenterology</i> , 2016 , 150, S392-S393	13.3	2
27	Patient considerations in the management of ulcerative colitis - role of vedolizumab. <i>Therapeutics and Clinical Risk Management</i> , 2015 , 11, 1235-42	2.9	2
26	An unusual case of diarrhea. <i>Gastrointestinal Endoscopy</i> , 2010 , 72, 436-7; discussion 436-7	5.2	2
25	The influence of hiv coinfection on the natural history of hcv infection. <i>Current Hepatitis Reports</i> , 2005 , 4, 131-137		2
24	Role of Hospital Teaching Status on Outcomes of Patients with Inflammatory Bowel Disease: A Nationwide Analysis. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 2216-2226	4	2
23	Inflammatory Bowel Disease and Cannabis: A Practical Approach for Clinicians. <i>Advances in Therapy</i> , 2021 , 38, 4152-4161	4.1	2
22	Impact of inflammatory bowel disease on hospital outcomes in acute ischemic stroke: a nationwide cohort study. <i>International Journal of Colorectal Disease</i> , 2021 , 36, 1759-1764	3	2
21	SARS-CoV-2 Immunization in Patients With Inflammatory Bowel Disease May Result in Disease Flares. <i>American Journal of Gastroenterology</i> , 2021 ,	0.7	2
20	Presentation and outcomes among inflammatory bowel disease patients with concurrent pneumatosis intestinalis: a case series and systematic review. <i>Intestinal Research</i> , 2020 , 18, 289-296	4.1	1
19	From Bad to Worse: The Relationship Between Opioid Use and Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 1188-1189	1.5	1
18	Obesity in Inflammatory Bowel Disease Is Associated with Early Readmissions Characterised by an Increased Systems and Patient-level Burden. <i>Journal of Crohns and Colitis</i> , 2021 , 15, 1807-1815	1.5	1
17	Increased Mortality and Healthcare Costs Upon Hospital Readmissions of Ulcerative Colitis Flares: A Large Population-Based Cohort Study. <i>Crohns & Colitis</i> 360, 2021 , 3,	1.4	1

16	Safety of biologics in inflammatory bowel disease patients with COVID-19. <i>International Journal of Colorectal Disease</i> , 2021 , 36, 2051-2055	3	1
15	Management of iatrogenic perforation during colonoscopy in ulcerative colitis patients: a survey of gastroenterologists and colorectal surgeons. <i>International Journal of Colorectal Disease</i> , 2018 , 33, 1607-1616	3	0
14	Endo-hepatology: An emerging field. <i>World Journal of Gastrointestinal Endoscopy</i> , 2021 , 13, 296-301	2.2	0
13	Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease-Authors' Reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 1026-1027	6.1	
12	P631 Development and validation of a clinical scoring tool for predicting treatment outcomes with vedolizumab in patients with ulcerative colitis. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S433-S433	1.5	
11	Hepatic Masses in a Patient With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2018 , 154, e5-e6	13.3	
10	Radiology Prep to the Rescue: Radiocontrast Enema After Failure of Oral Bowel Preparation for Patients with an Ileocolonic Fistula. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1363	0.7	
9	Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease-Authors' Reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 1121	6.1	
8	Images in clinical medicine. Fulminant ulcerative colitis. <i>New England Journal of Medicine</i> , 2010 , 362, 635	59.2	
7	O-24 YI Microbial Regulation of CD14+ Human Intestinal DCs Support ILC Production of IL-22 in IBD. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, S11	4.5	
6	P-241 YI Microbial Regulation of CD141 Human Intestinal DCs Support ILC Production of IL-22 in IBD. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, S107-S108	4.5	
5	Unusual cause of lower gastrointestinal bleed and abdominal pain. <i>Frontline Gastroenterology</i> , 2020 , 11, 337-338	2.6	
4	Increasing Pediatricians' Awareness of the Association between Anal Skin Tags and Earlier Diagnosis of Crohn's Disease. <i>Inflammatory Intestinal Diseases</i> , 2018 , 3, 40-42	2.5	
3	Healthcare Maintenance in the Patient with Inflammatory Bowel Disease: High-Yield Interventions. <i>Clinical Gastroenterology</i> , 2021 , 171-197	0	
2	Corticosteroid and Biologic Use Not Associated With Adverse Outcomes for Inflammatory Bowel Disease Patients Hospitalized With COVID-19.. <i>Gastroenterology Research</i> , 2021 , 14, 324-333	1.8	
1	Treatment Guided by Polymerase Chain Reaction Stool Testing Does not Alter Outcomes for Patients With Inflammatory Bowel Disease.. <i>Journal of Clinical Medicine Research</i> , 2021 , 13, 572-574	2.9	